

Amendments to the Specification:

Please replace the first paragraph on page 1, after the title with the following paragraph:

Cross Reference to Related Application

This application is a continuation of U.S. No. 09/159,027 filed September 23, 1998, now abandoned, which is a continuation of U.S. 08/793,048 filed November 1, 1996 now abandoned, from PCT National filing of PCT/EP95/01494 filed April 20, 1995 under PCT Article 34 on March 13, 1996, and which claims foreign priority benefits under 35 U.S.C. 119 of EPO 94810244.7 filed May 2, 1994.

On page 5 replace the 2nd paragraph with the following:

In the chimeric protein of the invention, the preferred antigen binding domain is a single-chain recombinant antibody (scFv) comprising the light chain variable domain (V_L) bridged to the heavy chain variable domain (V_H) via a flexible linker (spacer), preferably a peptide. Advantageously, the peptide consists of about 10 to about 30 amino acids, particularly naturally occurring amino acids, e.g., about 15 naturally occurring amino acids. Preferred is a peptide consisting of amino acids selected from L-glycine and L-serine, in particular the 15 amino acid peptide consisting of three repetitive units of Gly-Gly-Gly-Gly-Ser (residues 1-5 of SEQ ID NO: 12). Advantageous is a single chain-antibody wherein V_H is located at the N-terminus of the recombinant antibody. Preferred is a chimeric protein wherein the single-chain recombinant antibody has an above-defined preferred specificity, e.g., a chimeric protein comprising a single-chain recombinant antibody wherein the heavy chain variable domain and the light chain variable domain are derivable from a monoclonal antibody, e.g., a murine monoclonal antibody, directed to the human growth factor receptor HER2, such as a murine monoclonal antibody selected from the group consisting of FSP16, FSP77, FRP5 and FWP51.

On page 7 replace the last two paragraphs with the following:

Primers for the amplification of the L3T4/CD4D3/D4cDNA:

'Upstream'-5'Lyt-2/CD8-specific oligonucleotide #8761¹):

#8761: 5'-AGCTTCTAGAGTTTCAGAGCACAGCTCTCACGGCC-3' (SEQ ID NO: 13)

'Downstream'-3'Lyt-2/CD8-specific oligonucleotide #8762¹):

#8762: 5'-TCGATCTAGAGTCTGGTTCACCCCTCTGG-3' (SEQ ID NO: 14)

Please delete the paragraph on page 12, lines 16-24, and replace it with the following paragraph:

Advantageously, the DNA construct of the invention comprises a fourth part which is located upstream of the first part (the antigen binding domain) and which encodes a leader peptide. Preferably, the fourth part of the DNA construct of the invention encodes a leader peptide of an immunoglobulin (Ig) gene, e.g. an Ig heavy chain leader peptide. The Ig heavy chain leader peptide promotes targeting of nascent polypeptides to the lumen of the endoplasmic reticulum; it is subsequently cleaved off and the protein is sorted through the Golgi and the membrane to its transmembrane location. Particularly preferred is a leader peptide having the sequence: Met-Ala-Trp-Val-Trp-Thr-Leu-Leu-Phe-Leu-Met-Ala-Ala-Ala-Lys-Val-.Pro-Lys (residues 1-18 of SEQ ID NO: 6).

Please delete the paragraph on page 22, lines 33-36, and replace it with the following paragraph:

Figure 1: Structure of the pL(F4Z)SN retroviral vector. A cDNA encoding amino acid residues number 184-370 of the CD 4 immunoglobulin like D3 and D4 domains is derived by PCR and subcloned into the XbaI site of the PL(FX)SN vector. Amino acid sequences of the fusion boundaries are shown in the single letter code (SEQ ID NOS 15 and 16).

Replace Figure 1 with new Figure 1, appended.